华润三九(000999) - 2023 Q1 - 季度财报

Financial Performance - The company's revenue for Q1 2023 reached ¥6,352,408,318.71, representing a 49.46% increase compared to ¥4,194,386,685.74 in the same period last year[4] - Net profit attributable to shareholders was ¥1,151,030,150.88, up 36.90% from ¥838,713,628.38 year-on-year[4] - The net profit excluding non-recurring gains and losses was ¥1,131,213,788.87, reflecting a 41.86% increase from ¥797,413,610.83 in the previous year[4] - Revenue for Q1 2023 reached CNY 6,352,408,318.71, a 49.46% increase compared to CNY 4,250,226,596.43 in the same period last year[10] - Total operating revenue for Q1 2023 reached CNY 6,352,408,318.71, a significant increase of 49.5% compared to CNY 4,250,226,596.43 in Q1 2022[21] - Net profit for Q1 2023 was CNY 1,229,459,986.52, representing a year-over-year growth of 44.7% from CNY 849,604,681.09 in Q1 2022[21] - Operating profit increased to CNY 1,513,898,999.37, up 47.4% from CNY 1,026,677,610.57 in the same period last year[21] Cash Flow and Assets - The company's cash flow from operating activities decreased by 32.99% to ¥301,166,852.20, down from ¥459,140,529.66 in the same quarter last year[4] - Net cash flow from operating activities decreased by 32.99% to CNY 301,166,852.20, down from CNY 449,424,955.24 in the previous year[10] - Cash inflow from operating activities totaled CNY 6,156,670,173.57, up from CNY 4,276,978,435.80 in Q1 2022[23] - Total assets at the end of the reporting period were ¥37,879,854,016.08, a 39.66% increase from ¥27,122,781,699.16 at the end of the previous year[5] - Total assets increased to CNY 37,879,854,016.08, compared to CNY 27,122,781,699.16 at the end of Q1 2022, reflecting a growth of 39.5%[20] Shareholder Information - The number of ordinary shareholders at the end of the reporting period was 28,162[13] - The largest shareholder, China Resources Pharmaceutical Group, holds 62.99% of the shares[13] - The company has not disclosed any related party transactions among its top shareholders, ensuring transparency in its shareholder structure[14] Investments and Acquisitions - The company completed the acquisition of control over Kunming Pharmaceutical Group Co., Ltd., which significantly impacted its financial metrics[9] - The company completed the acquisition of a 28% stake in Kunming Pharmaceutical Group Co., Ltd. for a total transaction price of RMB 2.902 billion, with a per-share transfer price of RMB 13.67[15] - The company is focused on expanding its market presence and enhancing its product portfolio through strategic acquisitions and investments in R&D[15] - The company plans to continue expanding its market presence and investing in new technologies and products[10] Liabilities and Equity - Total liabilities rose to CNY 14,728,791,237.19, up from CNY 9,589,366,999.99, marking a 53.5% increase year-over-year[20] - Shareholders' equity attributable to the company increased by 6.87% to ¥18,177,577,940.58 from ¥17,009,633,485.53 at the end of the last year[5] - The company's equity attributable to shareholders reached CNY 18,177,577,940.58, an increase from CNY 17,009,633,485.53 in Q1 2022[20] Research and Development - Research and development expenses rose to CNY 132,597,016.85, an increase of 27.3% compared to CNY 104,151,173.24 in Q1 2022[21] Inventory and Receivables - Accounts receivable increased by 67.77% to ¥6,857,416,276.69 from ¥4,087,323,874.81 year-on-year[9] - Inventory grew by 73.56% to ¥4,337,017,034.56 from ¥2,498,868,530.92 in the same period last year[9] - Accounts receivable rose to RMB 6.86 billion, compared to RMB 4.09 billion at the beginning of the year, marking an increase of approximately 67.5%[19] - Inventory levels increased to RMB 4.34 billion from RMB 2.50 billion, indicating a growth of around 73.5%[19] Cash and Cash Equivalents - Cash and cash equivalents rose by 69.23% to ¥5,330,115,565.97 compared to ¥3,149,708,926.94 in the previous year[9] - Cash and cash equivalents increased to RMB 5.33 billion from RMB 3.15 billion, reflecting a growth of about 69.5%[19] - The ending balance of cash and cash equivalents reached ¥4,436,059,607.81, an increase from ¥2,774,870,713.46 at the end of Q1 2022[25]